Separately, Azurity Pharmaceuticals agreed to buy Matinas BioPharma Nanotechnologies, including MAT2203 and the LNC platform, for $4 million upfront.
The Azurity deal includes up to $17.5 million in milestones, mid-single-digit royalties, and targets a fourth-quarter 2026 close alongside the GH Power combination.
Matinas BioPharma to combine with GH Power
Matinas BioPharma agreed to combine with GH Power to form a NYSE-listed clean energy and critical minerals company focused on modular reactor systems.
GH Power holders are expected to own about 91% of the combined company on a fully diluted basis; Matinas holders about 9%.
Matinas shares are expected to convert into the right to receive 0.1 share of the new parent company at closing.
MTNB•
